Austedo is a brand name for deutetrabenazine, a medication used to treat tardive dyskinesia and chorea associated with Huntington's disease [1][2].
What is Tardive Dyskinesia?
Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive body movements. These movements can affect the face, tongue, lips, jaw, trunk, and extremities. It is often a side effect of long-term use of dopamine-blocking medications, particularly antipsychotics [3].
How does Austedo work?
Austedo works by reducing the levels of a neurotransmitter called dopamine in the brain. Dopamine plays a role in controlling movement, and an excess of it can lead to the involuntary movements seen in tardive dyskinesia and Huntington's disease [2]. Deuteration, the key difference in Austedo's chemical structure, allows it to remain in the body longer and bind to its target more effectively, potentially requiring less frequent dosing compared to older medications like tetrabenazine [1].
What are the side effects of Austedo?
Common side effects of Austedo can include drowsiness, insomnia, and upper respiratory tract infections. More serious side effects may involve changes in mood, depression, suicidal thoughts, and the risk of developing parkinsonism (symptoms similar to Parkinson's disease) [2]. It's important to discuss any potential side effects with a healthcare provider.
When does Austedo's patent expire?
Understanding patent expiry is crucial for predicting when generic versions of a drug might become available. Information on specific patent expiry dates for Austedo can be found through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods [4].
What are the alternatives to Austedo for tardive dyskinesia?
Besides Austedo, other medications are available for managing tardive dyskinesia. These include other vesicular monoamine transporter 2 (VMAT2) inhibitors, such as valbenazine (Ingrezza), as well as older, less specific dopamine-blocking agents in certain circumstances. The choice of treatment depends on individual patient needs, response to medication, and potential side effects [5].
How does Austedo compare to other VMAT2 inhibitors?
Austedo and valbenazine are both VMAT2 inhibitors, but they have differences in their chemical structure and pharmacokinetic profiles. Deutetrabenazine (Austedo) uses deuterium, a heavier isotope of hydrogen, which alters how the drug is metabolized in the body. This can lead to more consistent drug levels and potentially a different side effect profile compared to valbenazine [1][5].
Can Austedo treat Huntington's disease?
Yes, Austedo is approved for the treatment of chorea, a type of involuntary movement, associated with Huntington's disease. Huntington's disease is a progressive neurodegenerative disorder that affects movement, cognition, and behavior [2].
What is the price of Austedo?
The cost of Austedo can vary significantly depending on insurance coverage, pharmacy, and dosage. Patients often look for information regarding the drug's price and potential financial assistance programs [4].
Who manufactures Austedo?
Austedo is manufactured by Teva Pharmaceuticals [1].
What clinical data supports Austedo's use?
Clinical trials have demonstrated Austedo's efficacy in reducing the severity of tardive dyskinesia and chorea in Huntington's disease. These studies have evaluated various dosages and their impact on movement scores and patient-reported outcomes [2].
What regulatory approvals does Austedo have?
Austedo has received approval from regulatory agencies, such as the U.S. Food and Drug Administration (FDA), for its indicated uses. These approvals are based on comprehensive reviews of safety and efficacy data from clinical trials [2].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/